title: [Evaluation of coagulopathies and fibrinolytic abnormalities in central retinal vein occlusion in patients under 60 years of age].
abstract: OBJECTIVE
  To investigate the association of thrombophilic and fibrinolytic factors with central retinal vein occlusion (CRVO) in patients under 60 years of age.
  
  
  METHODS
  A prospective, observational study of 21 patients with CRVO compared with an age- and sex-matched control group of 23 volunteers was performed. All participants were tested for: cholesterol, hypertension, factors VIII, IX, and XI, homocysteine, antiphospholipid antibodies, antithrombin III, proteins C and S, protein Z and protein Z antibodies, resistance to activated protein C, factor V Leiden mutation, prothrombin mutation, MTHFR genotypes, plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen activator (t-PA) polymorphisms.
  
  
  RESULTS
  There was a significantly higher rate of hyperhomocysteinemia (23.8% versus 0%, P=0.018) in CRVO patients. Increased level of factor VIII was more common in the CRVO group at diagnosis (23.8% versus 0%, P=0.018) but no significant difference was observed after one month (P=0.1). Hypercholesterolemia was more common in the CRVO group (42.8% versus 17.4%, P=0.09). Thirty-eight percent of patients with CRVO were hypertensive. Frequencies of other hypercoagulable states were rare. No significant differences were observed for hereditary fibrinolytic abnormalities.
  
  
  CONCLUSIONS
  Among the coagulopathies studied, hyperhomocysteinemia appears to be a risk factor for central retinal vein occlusion in patients under 60 years of age. Conversely, polymorphisms of fibrinolytic factors do not appear to play a role in this population.
authors.affiliation: Service ophtalmologie, centre hospitalier universitaire Jean-Minjoz, 3, boulevard Alexandre-Fleming, 25030 Besançon cedex, France. sayana_tea@yahoo.fr
authors.forename: S
authors.initials: S
authors.lastname: Tea
authors.forename: M
authors.initials: M
authors.lastname: Barrali
authors.forename: E
authors.initials: E
authors.lastname: Racadot
authors.forename: B
authors.initials: B
authors.lastname: Delbosc
mesh_terms: D000328:Adult; D017668:Age of Onset; D001778:Blood Coagulation Disorders / Q000097:blood / Q000150:complications / Q000453:epidemiology* / Q000235:genetics; D001779:Blood Coagulation Factors / Q000032:analysis; D016022:Case-Control Studies; D004252:DNA Mutational Analysis; D005260:Female; D005787:Gene Frequency; D006801:Humans; D020138:Hyperhomocysteinemia / Q000097:blood / Q000196:embryology* / Q000209:etiology / Q000235:genetics; D008297:Male; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000235:genetics; D015995:Prevalence; D012170:Retinal Vein Occlusion / Q000097:blood / Q000453:epidemiology* / Q000209:etiology / Q000235:genetics
chemical_list: D001779:Blood Coagulation Factors; D017395:Plasminogen Activator Inhibitor 1; C051321:SERPINE1 protein, human; C573423:MTHFR protein, human; D042965:Methylenetetrahydrofolate Reductase (NADPH2)